ResMed Faces Securities Investigation by Pomerantz Law Firm
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices involving ResMed Inc. (NYSE: RMD) and its officers or directors, following a drop in the company's stock price after it reported lower-than-expected financial results for Q4 2026. ResMed disclosed that approximately $42 million of field safety notification expenses related to leaks in some Astral respirators negatively impacted its adjusted gross margins and operating income. On this news, ResMed’s stock fell by $11.30 per share (5.06%) on August 7, 2026. Pomerantz LLP is a well-known firm specializing in corporate litigation and has previously secured multimillion-dollar damages for class members.
Tickers: $RMD
Topics: financial_disclosure investor_protection stock_price_drop